Topic: FDA (Food & Drug Administration)

Ticker: FDA moves to ban menthols; Senate stonewalls pot in Granite State

• Pass the hemp: Colorado prepares to regulate the plant like any other food ingredient
• Pharmaceutical CBD bill heads to Colorado governor
• GW Pharmaceuticals’ CEO talks Epidiolex, future of cannabidiol medicine
• Federally legal hemp gets jolt from Republican Sen. Mitch McConnell
• CBD could be in the fast lane to Colorado pharmacies
• Marijuana-based anti-seizure drug shows strong study results
• Cannabinoids on local grocery shelves, but for how long?
• World Health Organization: Initial review of CBD doesn’t warrant scheduling
• Scientists call on feds to allow research on CBD for pets
• DEA finalizing Schedule II status for synthetic THC drug Syndros
• “A significant event”: CBD-based pharma drug Epidiolex presented to FDA for approval
• FDA sends warning letters to CBD companies, including Colorado’s CW Hemp
• Race for CBD medication breakthrough: Is pharma firm’s boon the hemp industry’s doom?
• FDA hints it may crack down on marijuana products that claim health benefits
• CBD on the international stage: WHO committee delving into science, control status of cannabis compound
• Federal ban on marijuana has created ‘regulatory vacuum’ says new study
• Op-ed: DEA position statement on CBD, hemp and Farm Bill “reckless and illegal”
• In the DEA’s words: Agency stance on CBD, hemp products and the Farm Bill
• Utah told scientists to study medical marijuana before they would legalize it. It could take years
• “People are desperate”: Parents, doctors place epileptic children in trials to get FDA approval of CBD oil
• Jeff Sessions could have power to unilaterally write federal drug policy, say critics of new bill
• Cannabis firms in Colorado, Florida partner to provide pharma-quality medical marijuana products
• Opioid epidemic is FDA’s top priority, says Trump’s pick to head agency
• Synthetic THC drug Syndros poised for Schedule II classification

• 1
• 2
• Next »